# NOAC Portuguese Real World Study

> **NCT04808934** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Stroke
- Systemic Embolism
- Major Bleeding

## Interventions

- **DRUG:** Apixaban
- **DRUG:** dabigatran
- **DRUG:** rivaroxaban
- **DRUG:** VKAs

## Key facts

- **NCT ID:** NCT04808934
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to COVID19 pandemic. Several delays affected this study, therefore company decided to not conduct the study. It was cancelled prior to any enrollment.
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808934, "NOAC Portuguese Real World Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04808934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*